CanSino Biologics receives approval from the Food and Drug Administration to conduct clinical trials of recombinant trivalent polio vaccine

July 18, 2025  Source: drugdu 86

"/July 16, CanSino (688185/06185) announced that it had recently received the "Drug Clinical Trial Approval Notice" for the recombinant trivalent polio vaccine (Sf-RVN cells) approved and issued by the National Medical Products Administration. The registration classification of this vaccine is a preventive biological product in category 1.2: The application is for registration of clinical trials of domestically produced drugs. The approval conclusion is to agree to conduct clinical trials for the prevention of poliomyelitis caused by polio virus infection type I, type II, and type III.

The recombinant polio vaccine is prepared through protein structure design and VLP assembly technology, has good safety and immunogenicity, and does not contain viral genetic material. The vaccine is currently undergoing Phase I/II clinical trials in Indonesia.

In the first quarter of 2025, CanSino Biologics achieved revenue of 137 million yuan and a net profit attributable to shareholders of the parent company of -11.55 million yuan.

https://finance.eastmoney.com/a/202507163458852082.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.